August 6, 2020, Rafael Pharmaceuticals announced that they had reached the goal of enrolling 500 patients into their phase three study of CPI613 (devimistat) plus modified Folfirinox in the treatment of Stage 4 Pancreatic Cancer. I also hear that the recruiting process took about a year and a half less than was expected. Congratulations Rafael Pharmaceuticals!!!!!!
See this article: https://www.globenewswire.com/news-release/2020/08/06/2074264/0/en/Rafael-Pharmaceuticals-Achieves-Target-Enrollment-of-500-Patients-in-Pivotal-Phase-3-Trial-AVENGER-500-of-CPI-613-%EF%B8%8F-devimistat-for-Patients-with-Metastatic-Pancreatic-Cancer.html
CPI613 can still be made available through compassionate use. Have your doctor download and fill out the forms. And other options can be found at PanCan.
3 thoughts on “August 6, 2020 GREAT NEWS!!!”
Thank you, Earl! That is excellent news! All the best to you. 🙂
What is their projection for when the phase 3 study will be done? How much time until they announce results from that?
HOPEFULLY by early next year maybe late this year cannot be soon enough